Investigational drug · Phase 3
EA-230
Also called: hour
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "EA-230"
First trial start
2026
Oct 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EA-230", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease (CAD)
- Coronary Artery Bypass Graft Surgery(CABG)
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "EA-230" as an intervention, largest first.
- A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.Pivotal-lookingRecruiting
EBI Anti Sepsis BVIndustry
NCT07357675 · 300 participants (planned) · Start Oct 29, 2026 · Primary completion Oct 1, 2027
Drug: EA-230 90mg/kg/hour; Placebo · For: Coronary Artery Disease (CAD); Coronary Artery Bypass Graft Surgery(CABG)
Sites: Rochester, Minnesota; Pittsburgh, Pennsylvania; Ghent, Belgium · 6 sites in all
- Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)Pivotal-lookingStatus unknown
Radboud University Medical CenterAcademic, hospital or other
NCT03145220 · 180 participants · Start Jun 2016 · Primary completion Oct 2018
Drug: EA-230 · For: Systemic Inflammatory Response Syndrome; Coronary Artery Bypass Grafting
Sites: Nijmegen, Netherlands
- PK/PD of EA-230 During EndotoxemiaCompleted
Radboud University Medical CenterAcademic, hospital or other
NCT02629874 · 60 participants · Start Feb 2015 · Primary completion Jul 2015
Drug: EA-230; Endotoxin and 1 more · For: Endotoxemia; Systemic Inflammatory Response
Sites: Nijmegen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- High-resolution 3D printed microfluidic immunoaffinity solid-phase extraction columns.
Skaggs TB, Miner DS, Nordin GP, et al. · Talanta 2027
- Terbium-modified poly(diphenylamine orange) sensor enabling sustainable monitoring of imatinib: Voltammetric and DFT insights.
Hosny NM, Frontera A, Darwish IA · Talanta 2027
- Maternal piromelatine treatment is associated with attenuated behavioral alterations and sex-specific changes in hippocampal pCREB/BDNF signaling in adult offspring following prenatal constant-light exposure.
Stoyanova T, Ivanova P, Tchekalarova J · Behav Brain Res 2027
- Narcolepsy: Current State and Future Prospects.
Morse AM · Neurol Clin 2027
- Catheter-directed thrombolysis to facilitate Fogarty thromboembolectomy in chronic tibial artery occlusion.
Nasr H, Almudaiheem FA, Ouda MA, et al. · J Vasc Surg Cases Innov Tech 2027
- DCDA-Net: A depthwise convolution dilated attention network with temporal weighted loss for seizure prediction.
Dong X, Li H, Chen Q, et al. · Neural Netw 2027
Also in development for Coronary Artery Disease (CAD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.